Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05332002 · ClinicalTrials.gov registry record · Phase 2
sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
A Phase 2 study of Gastro-Intestinal Cancer, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 6
- Study locations
NCT05332002 is a Phase 2 study of Gastro-Intestinal Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 38 participants. The trial reports 6 study locations across 1 state.
The verdict
NCT05332002, a Phase 2 study of Gastro-Intestinal Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.
Conditions Studied
Interventions
- DRUG Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI)
Study Locations (6)
New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital - Hamilton
- RWJBarnabas Health - Monmouth Medical Center Southern Campus - Lakewood
- RWJBarnabas Health - Monmouth Medical Center - Long Branch
- Rutgers Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset - New Brunswick
- RWJBarnabas Health - Newark Beth Israel Medical Center - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2026-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05332002
The ClinicalTrials.gov registry entry for NCT05332002 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastro-Intestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI) is the first listed.
NCT05332002 reports 6 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05332002 about?
NCT05332002 is a clinical study titled "sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)". The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to ch...
What is the current status of trial NCT05332002?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2022-07-13. Estimated completion is 2026-08-01.
What conditions does trial NCT05332002 study?
This clinical trial studies the following conditions: Gastro-Intestinal Cancer.
What interventions are being tested in trial NCT05332002?
The interventions under investigation include: Four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI) (DRUG).
Who is sponsoring clinical trial NCT05332002?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05332002 being conducted?
This trial has 6 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.